Enhancing innate immunity
Patented technology for Activated NK/NKT/γδT Cell Therapy
NK cells, NKT cells, and γδTcells are types of lymphocytes that are a part of the innate immune system. These cells have the ability to recognize and attack cancer cells without receiving instructions from other immune cells. NKT cells and γδT cells, however, also have the characteristics of T cells, and like killer T cells, may also be specifically activated by dendritic cells, thus making it possible to have pinpoint recognition of cancer cells. γδ T cells have a variety of receptors on the cell surface, and can sensitively detect changes in which normal cells become cancerous.
Technology has been developed to culture NK cells, NKT cells, and γδTcells in large quantities in a well-balanced manner outside the body, activate them, and then return them to the body.
Activated NK / NKT / γδT cell therapy is a treatment that uses these activated immune cells to enhance innate immunity as well as using adaptive immunity in order to effectively and specifically fight cancer.
This treatment is administered through intravenous infusion. NK cells, NKT cells, and γδT cells circulate through the body, and as cancer cells are identified, they are attacked and killed immediately.
1. Medical Consultation
Our physicians will consult with patients and in order to understand the patient’s full information impacting treatment. All factors including diagnostic imaging tests, bloodwork, medical history, current physical problems, work, lifestyle, family will be taken into consideration while recommending the best treatment and joint plan for each individual.
2. Initial testing
For the activated NK/NKT/γδT cell therapy, initial testing including tumor markers and infectious disease testing will be performed. Other testing including genetic testing, immune response testing (immunogram), CTC (circulating tumor cells) and cell free DNA testing can also be done upon request.
3. Blood draw and administration
A small amount of venous blood is collected to create the activated NK/NKT/γδT cell therapy. The treatment is created in 14 days, and then can be administered. This blood drawing and administering of therapy is repeated a total of six times every 2 weeks for one round (kur) of therapy.
* Blood collection is done by normal venipuncture.
* Administration is through intravenous drip.
4. Evaluation of treatment
At our clinic, we evaluate the patient’s progress and efficacy of treatment at baseline prior to treatment, immediately after the end of the first round, and then again 3 months after the first round of treatment. Prior to and at the end of the treatment course, we evaluate the patient’s QOL, immune response test (immunogram), tumor markers, and imaging studies. 3 months after completion, the patient’s QOL is reevaluated, the immunogram, tumor markers, and imaging studies are monitored in consultation with the patient to determine a future plan.
As the activated NK cell therapy is created using the patient’s own immune cells, there are little to no side effects. Rarely, a strong immune response may cause a fever of 37-38˚C within hours of administration, however such reactions usually subside within 24 hours.
Targeted medical conditions and symptoms
- Cancer (any type of cancer, any stage of cancer)
- Cancer prevention, recurrence or metastasis prevention
- Anti-aging or well-aging